| Adj-17 | Indications for antibody therapy |
|---|---|
| Grade of recommendation A | a. Patients with HER2-overexpressing tumors with a diameter ≥ 1 cm (immunohistochemical score 3+ and/or ISH-positive) should receive (neo-)adjuvant treatment with trastuzumab for one year. |
| Level of evidence 1b | (NICE 2009; NZGG 2009) |
| Grade of recommendation B | b. Adjuvant treatment with trastuzumab should preferably be started simultaneously with the taxane phase of adjuvant chemotherapy. |
| Level of evidence 2a | (Petrelli F et al. 2011) |
| c. If there is an indication for chemotherapy in tumors < 10 mm, trastuzumab should be given additionally. | |
| GCP |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.